Evidence map›Paper›PMID 38532108›Full record

ArticleCancer immunology, immunotherapy : CII2024

Co-targeting CD47 and VEGF elicited potent anti-tumor effects in gastric cancer.

Kaiqi Zhang, Yuan Xu, Xusheng Chang, Caili Xu, Wenjing Xue, Dan Ding, Mingming Nie, Hui Cai, Jun Xu, Lu Zhan and 6 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 12 citations in OpenAlex.

  1. Advances inOncology letters · 2026
    Review
  2. Article
  3. Therapeutic potential of targeting macrophage polarization in metastatic gastric cancer: a review on core mechanisms and clinical progress.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 1 country.

Kaiqi Zhang *Department of Gastrointestinal Surgery, Changhai Hospital, Naval Medical University, Shanghai, 200433, China.
Yuan Xu *Department of Gastrointestinal Surgery, Changhai Hospital, Naval Medical University, Shanghai, 200433, China.
Xusheng Chang *Department of Gastrointestinal Surgery, Changhai Hospital, Naval Medical University, Shanghai, 200433, China.
Caili Xu *Department of Biological Medicines & Shanghai Engineering Research Center of Immunotherapeutics, School of Pharmacy, Fudan University, Shanghai, 201203, China.
Wenjing XueDepartment of Biological Medicines & Shanghai Engineering Research Center of Immunotherapeutics, School of Pharmacy, Fudan University, Shanghai, 201203, China.
Dan DingDepartment of Gastrointestinal Surgery, Changhai Hospital, Naval Medical University, Shanghai, 200433, China.
Mingming NieDepartment of Gastrointestinal Surgery, Changhai Hospital, Naval Medical University, Shanghai, 200433, China.
Hui CaiDepartment of Gastrointestinal Surgery, Changhai Hospital, Naval Medical University, Shanghai, 200433, China.
Jun XuDepartment of Gastrointestinal Surgery, Changhai Hospital, Naval Medical University, Shanghai, 200433, China.
Lu ZhanDepartment of Gastrointestinal Surgery, Changhai Hospital, Naval Medical University, Shanghai, 200433, China.
Jiangbo HanDepartment of Gastrointestinal Surgery, Changhai Hospital, Naval Medical University, Shanghai, 200433, China.
Tiancai CaiDepartment of Sanatorium and Nursing Section, Xiamen Special Service Health Center, Xiamen, 361005, China.
Dianwen JuDepartment of Biological Medicines & Shanghai Engineering Research Center of Immunotherapeutics, School of Pharmacy, Fudan University, Shanghai, 201203, China.
Li FengDepartment of Endoscopy Center, Minhang Hospital, Fudan University, 170 Xinsong Road, Shanghai, 201199, China. feng_li@fudan.edu.cn.
Xuyao ZhangDepartment of Biological Medicines & Shanghai Engineering Research Center of Immunotherapeutics, School of Pharmacy, Fudan University, Shanghai, 201203, China. xuyaozhang@fudan.edu.cn.
Kai YinDepartment of Gastrointestinal Surgery, Changhai Hospital, Naval Medical University, Shanghai, 200433, China. kyin67@smmu.edu.cn.
Second Military Medical University · CNFudan University · CNChanghai Hospital · CN

Funding

Medical Innovation Research Program of Science and Technology Commission of Shanghai Municipality 21Y11913100National Key Research and Development Program of China 2023YFC3404000National Key Research and Development Program of China 2023YFC3606600National Natural Science Foundation of China 32200745National Natural Science Foundation of China 82371781Shanghai Sailing Program 21YF1401900
6 · The paper itself

Abstract

backgroundCD47, serving as an intrinsic immune checkpoint, has demonstrated efficacy as an anti-tumor target in hematologic malignancies. Nevertheless, the clinical relevance of CD47 in gastric cancer and its potential as a therapeutic target remains unclear.

methodsThe expression of CD47 in clinical gastric cancer tissues was assessed using immunohistochemistry and Western blot. Patient-derived cells were obtained from gastric cancer tissues and co-cultured with macrophages derived from human peripheral blood mononuclear cells. Flow cytometry analyses were employed to evaluate the rate of phagocytosis. Humanized patient-derived xenografts (Hu-PDXs) models were established to assess the efficacy of anti-CD47 immunotherapy or the combination of anti-CD47 and anti-VEGF therapy in treating gastric cancer. The infiltrated immune cells in the xenograft were analyzed by immunohistochemistry.

resultsIn this study, we have substantiated the high expression of CD47 in gastric cancer tissues, establishing a strong association with unfavorable prognosis. Through the utilization of SIRPα-Fc to target CD47, we have effectively enhanced macrophage phagocytosis of PDCs in vitro and impeded the growth of Hu-PDXs. It is noteworthy that anti-CD47 immunotherapy has been observed to sustain tumor angiogenic vasculature, with a positive correlation between the expression of VEGF and CD47 in gastric cancer. Furthermore, the successful implementation of anti-angiogenic treatment has further augmented the anti-tumor efficacy of anti-CD47 therapy. In addition, the potent suppression of tumor growth, prevention of cancer recurrence after surgery, and significant prolongation of overall survival in Hu-PDX models can be achieved through the simultaneous targeting of CD47 and VEGF using the bispecific fusion protein SIRPα-VEGFR1 or by combining the two single-targeted agents.

conclusionsOur preclinical studies collectively offer substantiation that CD47 holds promise as a prospective target for gastric cancer, while also highlighting the potential of anti-angiogenic therapy to enhance tumor responsiveness to anti-CD47 immunotherapy.

Indexed as

NeoplasmsStomach NeoplasmsAnimalsCD47 AntigenDisease Models, AnimalHumansImmunotherapyLeukocytes, MononuclearNeoplasm Recurrence, LocalPhagocytosisVascular Endothelial Growth Factor ACD47 AntigenCD47 protein, humanVascular Endothelial Growth Factor AVEGFA protein, humanAngiogenic vasculatureAnti-CD47 therapyCombinational therapyInnate immunityVEGF

Identifiers

PMID38532108
PMCPMC10965671
OpenAlexW4393952614

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.